Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery by Vos, M.C. (Margreet) et al.
Contents lists available at ScienceDirect
Surgical Oncology
journal homepage: www.elsevier.com/locate/suronc
Natural history of well-differentiated liposarcoma of the extremity
compared to patients treated with surgery
Melissa Vosa,b,∗, Dirk J. Grünhagena, Hanna Koseła-Paterczykc, Piotr Rutkowskic, Stefan Sleijferb,
Cornelis Verhoefa
a Department of Surgical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015GD, Rotterdam, the Netherlands
bDepartment of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015GD, Rotterdam, the Netherlands
c Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Institute-Oncology Center, Wilhelma Konrada Roentgena 5, 02-781, Warsawa, Poland
A R T I C L E I N F O
Keywords:
Well-differentiated liposarcoma
Extremity
Natural history
Active surveillance
Surgery
A B S T R A C T
Background: Patients with well-differentiated liposarcoma (WDLPS) of the extremity are mostly treated surgi-
cally, thereby possibly inducing severe morbidities. Despite the excellent prognosis, the natural history is barely
studied. The aim of this study was to evaluate the natural history of extremity WDLPS by evaluating the outcome
of patients treated with active surveillance (AS), who thereby exhibited the natural history of extremity WDLPS,
and of patients treated surgically.
Methods: A large retrospective database of patients with extremity WDLPS was assessed to evaluate treatment, ded-
ifferentiation and disease-specific survival. Lastly, our experience with patients treated with AS was explored.
Results: Distant metastases (5/191 patients, 2.6%) were mainly seen after a dedifferentiated local recurrence.
Death of disease occurred in 4/191 patients (2.1%); two patients died from metastatic disease (although not
pathologically proven), two patients died of treatment-related complications. In our center, 24 patients are
treated with AS. Time of AS varied from 0.1 to 8.9 years (median 1.8). Four patients eventually underwent
surgery after a period of AS (range 14–52 months) because of symptoms and/or tumor growth. No areas of
dedifferentiation were found in these resection specimens. The other patients are still under active surveillance.
Conclusion: Since surgical treatment might induce morbidity and even mortality, there might be overtreatment
of these patients. Evaluation of the natural history of extremity WDLPS showed that AS could be a reasonable
option for selected patients. Prospective studies in patients with extremity WDLPS are needed to assess the safety
of AS as a treatment option.
1. Introduction
Well-differentiated liposarcoma (WDLPS) is the most common
subtype of liposarcoma, accounting for approximately half of all lipo-
sarcoma patients. Most WDLPS patients present with a deep-seated,
slowly growing and painless mass, most frequently located in one of the
extremities. WDLPS are low-grade tumors and have very little to no
metastatic potential. However, they can dedifferentiate into a more
aggressive subtype, thereby gaining the ability to metastasize [1]. Pa-
tients with extremity WDLPS have a good prognosis with very low
dedifferentiation rates and excellent survival rates of 90–100% after 10
years of follow-up [1]. Because of this indolent disease course, ex-
tremity WDLPS is considered borderline malignant, and is therefore
also called an atypical lipomatous tumor [1–3].
Despite of these disease characteristics, almost all patients undergo
(extensive) surgery, optionally preceded or followed by radiotherapy.
Although consensus has shifted from radical amputation to wide exci-
sion – and even marginal excision now is considered appropriate and
adequate more often in case of localization in one of the extremities –
patients still have to deal with the morbidities and complications in-
duced by surgery, such as loss of limb function and wound infections
[4–6].
To date, the natural history of extremity WDLPS has rarely been
described in these patients. While this is much more studied in other
borderline malignant tumors, such as desmoid-type fibromatosis
[7–11], no study has ever been published yet in extremity WDLPS
evaluating its natural history. Therefore, the aim of this study was to
describe the natural history of patients with extremity WDLPS and to
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T
initiate and open a discussion on the treatment of patients with ex-
tremity WDLPS by discussing active surveillance as a treatment option
for these patients. With this purpose we looked in detail into the disease
course of both treated and untreated patients with extremity WDLPS.
2. Methods
2.1. Data collection
Data of surgically treated patients with primary WDLPS located in
one of the extremities were extracted from the database previously
described by Vos et al. [12] This database was revolved around patients
diagnosed with primary liposarcoma in the extremity in the Erasmus
MC Cancer Institute in Rotterdam, the Netherlands, and the Maria
Skłodowska-Curie Institute-Oncology Center in Warsaw, Poland, be-
tween 1986 and 2015. Both centers are designated as tertiary referral
and expertise centers for soft tissue sarcoma. One patient in this cohort
eventually did not undergo surgery because of minimal complaints,
although at start there was the intent to operate, and was excluded.
Imaging, in particular an MRI scan, was part of the standard diagnostic
work-up in both expertise centers. In some patients the diagnosis was
confirmed by fluorescent in situ hybridization (FISH) for MDM2 am-
plification, but in most of the patients the diagnosis was based on his-
tological, morphological and/or immunohistochemical criteria. Pa-
tients who presented with a local recurrence or metastatic disease were
excluded in this dataset. Although these patients underwent surgery,
the results from this cohort gave rise to the current study and the dis-
cussion on treatment of these patients.
In the Erasmus MC Cancer Institute, Rotterdam, the Netherlands,
already a few selected patients are being treated with active surveil-
lance, thereby exhibiting the natural history of extremity WDLPS. These
patients were identified during weekly multidisciplinary tumor board
meetings, by the treating physicians and through the institutional da-
tabase on liposarcomas. This group also includes patients who initially
started with active surveillance but eventually underwent surgery after
a period of active surveillance because of anxiety, occurrence of/in-
crease in symptoms and/or tumor growth. Frequency of follow-up and
imaging during active surveillance was in accordance with the national
soft tissue sarcoma guidelines [13] and was similar to the follow-up
schedule of low-grade sarcomas, or more often if indicated: first two
years every 4 months, year three to five every 6 months and after five
years once a year, with an X-ray of the thorax yearly and a MRI scan if
indicated. Of these patients, data on characteristics such as primary or
recurrent tumor, age at start of active surveillance, symptoms, time of
active surveillance and vital status (death/alive) were obtained. If pa-
tients opted to undergo surgery after a period of active surveillance, the
resection specimen was examined for (areas of) dedifferentiation. Time
of active surveillance was defined as time between start of active sur-
veillance and last follow-up or date of surgery.
This study was approved by the local ethics committee and per-
formed in accordance with local ethics committee guidelines and na-
tional legislation.
2.2. Statistical analyses
All statistical analyses were performed by using SPSS (IBM SPSS
Statistics for Windows, Version 24.0, IBM Corporation, Armonk, NY,
USA). Categorical variables are shown as numbers with percentages in
parentheses and continuous variables as medians with the interquartile
ranges (IQRs) in parentheses. χ2-tests, Fisher's Exact tests and Mann-
Whitney U tests were used to test for differences in clinicopathological
variables between groups when appropriate. Two-sided p-values<
0.05 were considered statistically significant.
Table 1
Patient characteristics.
Total (N=191) Rotterdam (N=113) Warsaw (N=79) p-value$
N % N % N %
Sex Female 103 53.9 61 54.5 42 53.2 0.859
Male 88 46.1 51 45.5 37 46.8
Age at diagnosis (years)a 59 (49–67) 60 (50–68.5) 58 (48–64.5) 0.104
Site Lower extremity 163 85.3 97 86.6 66 83.5 0.556
Upper extremity 28 14.7 15 13.4 13 16.5
Size (cm)a 17 (12–23) 18.5 (13–23) 16 (10.5–20.3) 0.106
Resection margins R0 83 43.7 19 17.1 64 81.0 < 0.001
R1/R2 78 41.1 63 56.8 15 19.0
Unknown 29 15.3 29 26.1 0 0.0
Neoadjuvant treatment None 143 74.9 107 95.5 36 45.6 < 0.001‡
Radiotherapy 44 23.0 1 0.9 43 54.4
ILP 2 1.0 2 1.8 0 0.0
Unknown 2 1.0 2 1.8 0 0.0
Adjuvant treatment None 175 91.6 98 87.5 77 97.5 0.042‡
Radiotherapy 14 7.3 12 10.7 2 2.5
Unknown 2 1.0 2 1.8 0 0.0
Local recurrence None 154 80.6 79 70.5 75 94.9 < 0.001
Yes 37 19.4 33 29.5 4 5.1
Time to local recurrence (months)a 41 (15–57) 41 (15–57) 43 (21.5–64) 0.869
Dedifferentiation None 186 97.4 109 97.3 77 97.5 0.448‡
Yes 4 2.1 3 2.7 1 1.3
Unknown 1 0.5 0 0.0 1 1.3
Distant metastasis None 186 97.4 109 97.3 77 97.5 1.000‡
Yes 5 2.6 3 2.7 2 2.5
Time to metastasis (months)a 24 (18–26) 24 (21–25) 68.5 (17–120) 1.000
Survival Alive 174 91.1 98 87.5 76 96.2 0.110‡
Death of disease 4 2.1 3 2.7 1 1.3
Death of other/unknown cause 13 6.8 11 9.8 2 2.5
Follow-up (months)a 49 (24–75.5) 49.5 (19–82.5) 48 (27–74) 0.949
a Presented as median (interquartile range). $Calculated by χ2-tests (categorical data) or Mann-Whitney U tests (continuous data). ‡Fisher's Exact test.
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3. Results
3.1. Course of disease of the surgically treated patients – distant metastasis
In total, 191 patients with primary WDLPS located in the extremity
who were treated surgically were identified: 112 in the Rotterdam-co-
hort and 79 in the Warsaw-cohort. As described and discussed before
[12], there was a difference in the number of radical resections, use of
neoadjuvant and adjuvant radiotherapy and percentage of patients
experiencing a local recurrence between the two centers (Table 1). In
brief this study showed that an aggressive approach with radical sur-
gery and neoadjuvant/adjuvant radiotherapy led to excellent local
control, while a more conservative approach with enucleation of the
tumor (i.e. R1-resection) and without radiotherapy led to higher local
recurrence rates, but also that these differences in treatment did not
lead to a difference in disease-specific survival for patients with ex-
tremity WDLPS [12]. Distant metastases were scarcely observed, nei-
ther were dedifferentiation and death of disease, with a median follow-
up time of 49 months (IQR 24–75.5, Table 1). In total, five patients out
of 191 patients developed metastatic disease (Table 2). Three of these
five patients first developed a dedifferentiated local recurrence before
developing metastatic disease, the fourth patient developed a local re-
currence and a distant metastasis simultaneously. The local recurrent
tumor was confirmed by biopsy, showing WDLPS without any signs of
dedifferentiation, but no material from the metastatic site was obtained
for pathological examination. The patient is still alive, after 'palliative'
radiotherapy with a total of 24Gy, with a follow-up period of 60 months
(42 months after diagnosis of metastatic disease). The last patient de-
veloped massive distant metastases in lungs and liver as a first mani-
festation of recurrent disease, within four months since the prior follow-
up visit with a 'clean' chest X-ray, and died one month later. No data on
confirmation of the LPS diagnosis and dedifferentiation in the metas-
tases were available, although the aggressive course of disease suggests
either dedifferentiation or that these lesions were metastases from an-
other unknown primary tumor. So, it is questionable whether the last
two patients with 'metastases', without a dedifferentiated local recur-
rence, really had metastatic WDLPS.
3.2. Course of disease of the surgically treated patients - survival
Death of disease was also rarely observed in this group of patients (4
out of 191 patients), with a 5-year disease-specific survival of 98.3%
[12]. Two of the deceased patients were two of the patients with me-
tastatic disease described above; the other two deaths were both one
month after diagnosis of the primary tumor and turned out to be
treatment-related, instead of disease-related. One patient died a few
days after neoadjuvant treatment with isolated limb perfusion, and the
second patient a few days after surgical resection of the primary tumor
due to acute myocardial infarction.
3.3. Natural history of extremity WDLPS in untreated patients
These observations raised questions on the treatment of patients
with extremity WDLPS. Since patients only die of the disease after
dedifferentiation, dedifferentiation rates are low, dedifferentiation only
occurred in local recurrences after surgical removal of the primary
tumor, and surgery might induce morbidity and even mortality, we
could be overtreating these patients. This might especially apply for
patients with inconveniently localized or deep-seated and large tumors
(i.e. surgeries where chances of inducing morbidity are substantial)
without any debilitating symptoms, elderly patients and/or patients
with significant comorbidities.
Therefore, in the Erasmus MC Cancer Institute Rotterdam, the
Netherlands, already a few patients with extremity WDLPS have been
treated with active surveillance, in whom the natural history of ex-
tremity WDLPS can be studied. In all these patients, a conscious
decision for active surveillance was taken. Most of these patients have
local recurrent WDLPS without any (debilitating) symptoms (19 out of
24 patients treated with AS), in a smaller number of patients the pri-
mary tumor is treated with AS (5 out of 24 patients). Reasons for
choosing active surveillance included one, or a combination, of the
following motives: the absence of any debilitating symptoms, no/
minimal tumor growth, an inconvenient localization (i.e. minimal
chance of radical resection), and/or a high risk of inducing severe
morbidity during surgery. Follow-up of the patients treated with active
surveillance ranges from a few months to almost 9 years (median 22
months, IQR 10–51 months, total range 1–107 months) and the median
age at time of start of active surveillance was 70 years (IQR 62–74.5)
(Table 4). Of these 24 patients, four patients opted to undergo surgery
after a period of active surveillance, because of symptoms and/or tumor
growth. Time of active surveillance in these four patients was 14, 16, 24
and 52 months. After surgery, no areas of dedifferentiation were found
in any of the tumor specimens. The tumors of the remaining 20 patients
are still in situ (with a median follow up of 26 months, IQR 5–51
months). These patients are monitored according to the follow-up
schedule of low-grade sarcomas as stated in the national soft tissue
sarcoma guidelines, including imaging on indication, except for two
patients (one patient died to a cause unrelated to WDLPS, one patient is
lost to follow-up). Although some of the patients only have been treated
with active surveillance for a few months so far, there is no/minimal
growth of these tumors and they do not have any signs of dediffer-
entiation up to date, even not in the patient treated with active sur-
veillance for almost nine years.
4. Discussion
The cases described above in a large dataset of 191 surgically
treated patients with extremity WDLPS outline that patients do not or
seldom die because of extremity WDLPS, unless the recurrent tumor has
dedifferentiated, while two deaths were induced by its treatment. These
observations raised questions about the possible overtreatment of this
patient group, and led to a discussion on whether a more conservative
treatment or even no treatment at all (active surveillance) is more ap-
propriate and justified in selected cases.
In line with the results of our study, other studies of extremity
WDLPS have reported low rates of dedifferentiation [1,6,14,15], me-
tastatic disease [4,16] and mortality [17–19]. Despite these excellent
outcomes, treatment of these patients remains almost similar to that of
patients with more aggressive subtypes, such as dedifferentiated,
myxoid or pleiomorphic liposarcoma. The extent of treatment of ex-
tremity WDLPS is already under debate, with ongoing discussions re-
garding the harms and benefits of wide excision versus marginal exci-
sion, [4,6,20] and the use of neoadjuvant/adjuvant radiotherapy
[21,22]. To this debate, we can now add the question whether excision
– or treatment in general – is indicated at all. The morbidity and risks of
marginal resections (i.e. R1 resections) are generally quite low, but they
are still present and should be taken into account. The results of this
study, together with those of other studies reporting excellent survival
rates, indicate that not all cases of extremity WDLPS may require sur-
gical removal. In selected cases, especially in elderly patients, patients
with comorbidities and/or patients with inconveniently localized, large
and deep-seated tumors without any symptoms in whom surgical re-
section most probably will lead to substantial morbidity, it may be
appropriate and adequate to pursue conservative treatment in the form
of active surveillance. The appropriateness of active surveillance was
further underscored by the observation that it has been safe so far to
apply this approach in selected patients with extremity WDLPS who do
not experience any debilitating symptoms and who have inconveniently
localized tumors at the Erasmus MC Cancer Institute, although follow-
up is still short. In these patients, the natural history of extremity
WDLPS showed no/minimal growth of the tumors. In the few patients
(4/24) who did experience growth/symptoms after a period of active
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surveillance and therefore opted to undergo surgery, no dedifferentia-
tion was found in the specimens. However, it remains unknown whe-
ther it is preferable to remove these large and inconveniently localized
WDLPS quickly after diagnosis, or to observe them for a period of time
for possible tumor growth and/or dedifferentiation.
During treatment decision making numerous factors have to be
taken into consideration, balancing the risks and benefits of the treat-
ment for each patient. Radical local treatment leads to better local
control, but comes at the costs of morbidity, impaired functional out-
come and even mortality, but does not affect disease-specific survival
[12]. Factors that influence this balance include patient-related factors,
such as age, performance status, comorbidities and the patient's own
wish, and tumor-related factors, such as symptoms, localization, tumor
size and signs of dedifferentiation. A tumor localized in the extremity is
particularly suitable for an active surveillance approach, since tumor
growth can be monitored by physical examination – even by the patient
him/herself – and does not completely rely on imaging alone [23,24].
For example, for the 91-year old patient in our study who died due to
the treatment (Table 3), the risk of dying of an age-related disease (e.g.
cardiovascular disease, stroke, dementia) was probably higher than the
risk of developing dedifferentiated metastatic disease and dying as a
result of extremity WDLPS. In retrospect, we feel that active surveil-
lance with a natural course of disease might have been both feasible
and adequate in this case. In patients who are younger and fitter or who
have smaller and more favorable localized tumors (i.e. less complex
surgery), this consideration is likely to be different and surgery might
be the preferred option.
Active surveillance in WDLPS has been discussed and suggested
before, but such discussions have mainly focused on specific situations,
such as after resection of recurrent tumors, after surgical treatment of
the primary tumor, or for large inoperable primary tumors [22,25–27].
There is a distinct lack of studies and data regarding patients with ex-
tremity WDLPS who actually have been treated with active surveil-
lance. A further problem with previous studies is that overall or disease-
specific survival alone might not be the most appropriate outcome
measurements for this subgroup of patients, since survival rates ap-
proach 100% [1,17–19]. Other outcome measurements, such as quality
of life, are becoming more and more relevant. To date, no studies on
quality of life have been conducted in patients with extremity WDLPS.
On the one hand, quality of life of patients with active surveillance
might be better than those undergoing surgery, because they would
avoid the necessity of surgery and its related complications and mor-
bidities. On the other hand, their quality of life might be poorer than
those undergoing surgery, because living with a tumor in situ might
lead to tumor-related symptoms and cause anxiety.
A limitation of our study is that it was based on retrospective data –
inherent when studying rare diseases – which relies on accurate re-
cordkeeping and which has induced bias. We acknowledge that there is
most probably a selection bias in the patients currently treated with
active surveillance, although we believe that this type of treatment will
always be subject to some extent of selection bias, since patients with
symptoms most likely will refuse active surveillance and prefer surgical
treatment. Notwithstanding these assumptions and bias, this study was
set up to initiate a discussion regarding the (over)treatment of these
patients and to generate hypotheses for further research to test the
safety and feasibility of active surveillance in a larger prospective trial.
A second limitation was that not all diagnoses were confirmed by FISH
for MDM2 amplification. Furthermore, data regarding imaging was
missing, although imaging is part of the standard diagnostic work-up in
both expertise centers.
Since the life expectancy is high and unaffected by local treatment,
[12] we believe that active surveillance is feasible for selected cases, in
particular for elderly patients with comorbidities and minimal symp-
toms and/or for patients with a large, deep-seated or otherwise in-
conveniently localized tumor without symptoms in whom surgical re-
section most probably will lead to substantial morbidity. However,
further research is needed before active surveillance can be safely ap-
plied in daily clinical practice. Therefore, we propose a prospective
observational study to investigate the differences between surgical
treatment and active surveillance in patients with extremity WDLPS
regarding disease-specific survival, dedifferentiation rates, tumor
growth (using the RECIST criteria [28]) and quality of life, comparable
to the prospective studies in patients with desmoid-type fibromatosis
treated with active surveillance [10,29,30]. This future prospective trial
should include regular MRI imaging, allowing for timely intervention in
case of tumor growth and/or signs of dedifferentiation.
5. Conclusion
Although the numbers are small and the follow-up relatively short,
the evaluation of the natural history of extremity WDLPS illustrated
that active surveillance could be a reasonable option for selected pa-
tients. This highlights the observation that there might be an over-
treatment of these patients, since surgical treatment might lead to
morbidity and even mortality in patients with this borderline malignant
tumor. The harms and benefits of surgical treatment and active sur-
veillance should be carefully balanced, taking the extension and loca-
lization of the tumor (i.e. complexity of the surgery), comorbidities and
the indolent disease course into account. This especially applies for
elderly patients with comorbidities and/or patients with large, deep-
seated or otherwise inconveniently localized tumors without symptoms.
We propose to conduct a prospective observational study to assess the
safety and outcomes of active surveillance in this patient group.
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